Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Scientists inhibit tumor formation

By studying mice with skin cancer, researchers at the Huntsman Cancer Institute at the University of Utah discovered a way to inhibit a mutant gene found in up to 30 percent of human tumors.

9 May 2005

New drug may help treat certain forms of leukemia

A new experimental drug may be effective against a certain form of leukemia resistant to current treatments, research at UT Southwestern Medical Center shows.

2 May 2005

Giving children access to drug clinical trials is crucial, clofarabine approval shows

The accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) demonstrates the importance of offering children rapid access to new treatments through clinical trials, according to investigators at St. Jude Children's Research Hospital. Refractory or relapsed ALL is a disease that resists treatment.

2 May 2005

New prognostic markers help identify risk of relapse

A recently completed clinical study has found new prognostic markers that may help clinicians identify those children with leukaemia who are at high risk of relapse and are most in need of intensified treatment to improve their chance of survival.

1 May 2005

Children treated for soft tissue sarcomas at greater risk of second cancers

A new study has found that although children treated for soft tissue sarcomas are surviving longer than they did in the past, they have an increased risk for second cancers, especially when initial treatment combined radiation and chemotherapy. This is according to analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.

27 Apr 2005

Australian clinical trial of potent new anticancer drug (CYT997)

Up to 30 patients with advanced incurable solid-tumours are to be involved in clinical trials of a potent new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia Limited.

27 Apr 2005

National clinical trial examines new option for kidney cancer patients

The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.

27 Apr 2005

Herceptin in combination with chemotherapy reduces risk of breast cancer recurrence in women with with early-stage breast cancer

Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.

26 Apr 2005

P12 protein influences key cell-signaling pathway

New research shows that a protein produced by a cancer-causing virus influences a key signaling pathway in the immune cells that the virus infects. This stimulates the cells to divide, helping the virus spread through the body.

26 Apr 2005

High risk of second cancers in survivors of childhood soft tissue sarcomas

Children treated for soft tissue sarcomas have a significantly higher risk of developing subsequent cancers later in life, according to a new study. The study appears in the June 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, and indicates children treated with combined chemotherapy and radiation therapy, in particular, had greater risks of developing a new malignancy.

25 Apr 2005

Pattern of gene expression predicts multiple drug resistance, treatment failure in pediatric leukemia

The discovery of a specific pattern of gene expression linked to multiple-drug resistance of leukemic cells is giving researchers crucial information into why standard therapies fail to cure some children with acute lymphoblastic leukemia (ALL). This finding, from investigators at St. Jude Children’s Research Hospital, could lead to development of drugs that would overcome that resistance.

24 Apr 2005

Increasing benefit seen in novel drug AMN107, that treats Gleevec resistance

An investigational drug is producing powerful responses in patients resistant to Gleevec, the targeted therapy that helps most people diagnosed with chronic myeloid leukemia (CML), an international research team headed by investigators at The University of Texas M. D. Anderson Cancer Center is reporting.

23 Apr 2005

Day care in infancy protects against childhood leukaemia

Children who attend day care centres on a regular basis in the first few months of life are less likely to develop leukaemia than children who do not, finds a study published online by the BMJ.

22 Apr 2005

Enzyme that helps trigger the development of leukemia

Scientists at the University of North Carolina at Chapel Hill have identified an enzyme that helps trigger the development of leukemia, a cancer of blood cells.

21 Apr 2005

New gene linked to familial cancer

Scientists have identified a new gene that appears to be linked to a small but significant percentage of familial cancer cases – as well as seemingly randomly occurring malignancies.

20 Apr 2005

New era drug gives hope to Gleevec resistant leukaemia sufferers

Gleevec, a drug regarded by many as having "wonder drug" capabilities in the treatment of chronic myelogenous leukaemia (CML) and other cancers, has been revealed as having shortcomings in that some patients have undergone a relapse after building a resistance to the drug. For others with the advanced stage of the disease, the drug has failed to produce durable remissions.

19 Apr 2005

Gene expression pattern predicts multiple drug resistance

St. Jude Children's Research Hospital discovery of genetic links to multi-drug resistance gives clinicians new insight into the cause of treatment failure and suggests targets for novel anti-leukemic drugs

19 Apr 2005

Scientists reveal the shape of a protein that helps retroviruses break into cells

Retroviruses are among the trickier and more malicious disease agents, causing AIDS and cancers such as leukemia. The viruses manage to sneak into cells with the help of special protein assemblies scattered all over their surfaces. These retrovirus surface proteins cause the membrane envelope of the virus to fuse with the membrane of the cell, spilling virus RNA into the cell to wreak damage.

13 Apr 2005

Sildenafil prevents anti-cancer drug induced heart damage

Virginia Commonwealth University researchers have found that the popular impotence drug Viagra prevents damage to the heart from a potent chemotherapeutic agent frequently used in the treatment of breast cancer, leukemia and sarcomas.

5 Apr 2005

Method of gene therapy accurately corrects mutations in disease-causing genes

Harnessing the strength of a natural process that repairs damage to the human genome, a researcher from UT Southwestern Medical Center has helped establish a method of gene therapy that can accurately and permanently correct mutations in disease-causing genes.

5 Apr 2005